Journal article
Statin Use and Breast Cancer: Prospective Results From the Women's Health Initiative
JNCI : Journal of the National Cancer Institute, Vol.98(10), pp.700-707
05/17/2006
DOI: 10.1093/jnci/djj188
PMID: 16705124
Abstract
Background: Despite experimental observations suggesting that 3-hydroxy-3-methylglutaryl coenzyme A inhibitors (statins) have antitumor activity, clinical studies have reached mixed conclusions about the relationship between statin use and breast cancer risk. Methods: To investigate associations between potency, duration of use, and type of statin used and risk of invasive breast cancer, we examined data for 156 351 postmenopausal women who were enrolled in the Women's Health Initiative. Information was collected on breast cancer risk factors and on the use of statins and other lipid-lowering drugs. Cox proportional hazards regression was used to calculate hazard ratios (HRs) with 95% confidence intervals (CIs). Statistical tests were two-sided. Results: Over an average follow-up of 6.7 years, 4383 invasive breast cancers were confirmed by medical record and pathology report review. Statins were used by 11 710 (7.5%) of the cohort. Breast cancer incidence was 4.09 per 1000 person-years (PY) among statin users and 4.28 per 1000 PY among nonusers. In multivariable models, the hazard ratio of breast cancer among users of any statin, compared with nonusers, was 0.91 (95% CI = 0.80 to 1.05, P = .20). There was no trend in risk by duration of statin use, with HR = 0.80 (95% CI = 0.63 to 1.03) for <1 year of use, HR = 0.99 (95% CI = 0.80 to 1.23) for 1–<3 years of use, and HR = 0.94 (95% CI = 0.75 to 1.18) for ≥3 years of use. Hydrophobic statins (i.e., simvastatin, lovastatin, and fluvastatin) were used by 8106 women, and their use was associated with an 18% lower breast cancer incidence (HR = 0.82, 95% CI = 0.70 to 0.97, P = .02). Use of other statins (i.e., pravastatin and atorvastatin) or nonstatin lipid-lowering agents was not associated with breast cancer incidence. Conclusions: Overall statin use was not associated with invasive breast cancer incidence. Our finding that use of hydrophobic statins may be associated with lower breast cancer incidence suggests possible within-class differences that warrant further evaluation.
Details
- Title: Subtitle
- Statin Use and Breast Cancer: Prospective Results From the Women's Health Initiative
- Creators
- Jane A. Cauley - University of PittsburghAnne McTiernan - Fred Hutch Cancer CenterRebecca J. Rodabough - Fred Hutch Cancer CenterAndrea LaCroix - Fred Hutch Cancer CenterDouglas C. Bauer - University of California, San FranciscoKaren L. Margolis - University of MinnesotaElectra D. Paskett - The Ohio State UniversityMara Z. Vitolins - Wake Forest UniversityCurt D. Furberg - Wake Forest UniversityRowan T. Chlebowski - University of California, Los AngelesWomen's Health Initiative Research Group
- Contributors
- Robert Wallace (Contributor) - University of Iowa, Internal Medicine
- Resource Type
- Journal article
- Publication Details
- JNCI : Journal of the National Cancer Institute, Vol.98(10), pp.700-707
- DOI
- 10.1093/jnci/djj188
- PMID
- 16705124
- NLM abbreviation
- J Natl Cancer Inst
- ISSN
- 0027-8874
- eISSN
- 1460-2105
- Publisher
- Oxford University Press
- Language
- English
- Date published
- 05/17/2006
- Academic Unit
- Epidemiology; Injury Prevention Research Center; Internal Medicine
- Record Identifier
- 9984364404002771
Metrics
11 Record Views